Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography by Tomoda, Takeshi et al.
1 
 
Title page 
Title  
Combination of Diclofenac and Sublingual Nitrates is Superior to Diclofenac Alone in 
Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography  
 
Short title 
Sublingual nitrate with rectal NSAIDs for PEP 
 
Author Names 
Takeshi Tomoda1, Hironari Kato1, Toru Ueki2, Yutaka Akimoto3, Hidenori Hata4, 
Masakuni Fujii5, Ryo Harada6, Tsuneyoshi Ogawa7, Masaki Wato8, Masahiro Takatani9, 
Minoru Matsubara10, Yoshinari Kawai11, and Hiroyuki Okada1. 
 
Affiliation 
1, Department of Gastroenterology and Hepatology, Okayama University Graduate 
School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, 700-8558, Japan 
2, Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, 721-8511, 
Japan 
2 
 
3, Department of Gastroenterology, Iwakuni Clinical Center, Iwakuni, 740-8510, Japan 
4, Department of Gastroenterology, Mitoyo General Hospital, Kanonji, 769-1695, 
Japan 
5, Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama 
700-8511, Japan 
6, Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama 
700-8607, Japan 
7, Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, 
Hiroshima 730-8518, Japan 
8, Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, 
760-8557, Japan 
9, Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, 
Himeji, 670-8540, Japan 
10, Department of Internal Medicine, Sumitomo Besshi Hospital, Niihama, 792-8543, 
Japan 
11, Department of Gastroenterology, Onomichi Municipal Hospital, Onomichi 722-8503, 
Japan 
 
3 
 
Corresponding author  
Takeshi Tomoda, M.D., Ph.D. 
Department of Gastroenterology and Hepatology, Okayama University Graduate School 
of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, 
Okayama-city, Okayama 700-8558, Japan 
E-mail: tomotake79@yahoo.co.jp 
 
Conflicts of Interest and Source of Funding 
There are no conflicts of interest to declare, and the authors have not received any grant 
or other financial support for the work. 
 
Abbreviation 
ERCP, endoscopic retrograde cholangiopancreatography; NSAIDs, nonsteroidal anti-
inflammatory drugs; PEP, post ERCP pancreatitis; RCT, randomized controlled trials; 
EPST, endoscopic pancreatic sphincterotomy; EPBD, endoscopic papillary balloon 
dilation; SOD, sphincter of oddi dysfunction; AE, adverse effect; NNT, number needed to 
treat; OR, odds ratio; CI, confidence interval 
 
4 
 
Authors contributions 
TT and HK took part in the conception, design, and drafting of the article. TU, YA, HH, 
MF, RH, TO, MW. MT, MM, YK participated in the analysis and interpretation of the 
data. HO participated in the final approval of the article.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Abstract 
Background & Aims: Acute pancreatitis is a major adverse event of endoscopic 
retrograde cholangiopancreatography (ERCP). Rectal administration of non-steroidal 
anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis 
(PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We 
performed a randomized trial to assess whether the combination of NSAIDs and 
sublingual nitrate is more effective than NSAIDs alone in preventing PEP. 
 
Methods: In a prospective superiority trial, eligible patients underwent ERCP at 12 
endoscopic units in Japan, from March 2015 through May 2018. Patients were randomly 
assigned to groups given diclofenac suppositories (50 mg) within 15 minutes after the 
endoscopic procedure alone (diclofenac alone group, n=442) or in combination with 
sublingual isosorbide dinitrate (5 mg) 5 minutes before the endoscopic procedure 
(combination group, n=444). The primary endpoint was the occurrence of PEP. 
 
Results: Post-ERCP pancreatitis developed in 25 patients in the combination group 
(5.6%), and in 42 patients in the diclofenac alone group (9.5%) (relative risk, 0.59; 95% 
CI, 0.37–0.95; P=.03). Moderate to severe pancreatitis developed in 4 patients (0.9%) in 
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the combination group, and 10 patients (2.3%) in the diclofenac alone group (relative 
risk, 0.12; 95% CI, 0.13–1.26; P = 0.12). There was no serious adverse event related to 
the additional administration of sublingual nitrate. 
 
Conclusions: In a randomized controlled trial, we found that prophylaxis with rectal 
diclofenac and sublingual nitrate significantly reduces the overall incidence of PEP 
compared with diclofenac suppository alone. ClinicalTrials.gov, no: UMIN 000016274 
 
KEY WORDS: pancreas, inflammation, smooth-muscle relaxant, drug 
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Introduction 
Acute pancreatitis is the most important adverse event (AE) of endoscopic retrograde 
cholangiopancreatography (ERCP). Generally, post-ERCP pancreatitis (PEP) occurs in 
1–25% of patients [1-2]. PEP is usually mild or moderate; however, some cases may 
develop severe pancreatitis, which requires further intervention and leads to death in 
0.3–0.6% of the patients [3-6].  
Numerous pharmacological agents have been evaluated for the prevention of PEP. 
Several randomized trials, including a high-profile multicenter study, have confirmed 
the efficacy of rectal non-steroidal anti-inflammatory drugs (NSAIDs) in preventing PEP 
[7-10]. Routine rectal administration of diclofenac or indomethacin, immediately before 
or after an ERCP has been recommended to minimize the risk of PEP in the European 
Society of Gastrointestinal Endoscopy (ESGE) and Japanese Society of Hepato-Biliary-
Pancreatic Surgery (JHBPS) guidelines [11] [12]. Moreover, in 2 randomized controlled 
trials (RCTs), positive results have been reported by administering sublingual nitrate to 
prevent PEP [13, 14]. Nitrate is a smooth-muscle relaxant, and increases pancreatic 
parenchymal blood flow [15]. Recently, it was demonstrated in a RCT that a combination 
of sublingual nitrate and rectal NSAIDs is more effective than NSAIDs alone in 
preventing PEP [16]. The study showed that the relative risk of PEP reduced by 56.2% 
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with this treatment, which is simple, inexpensive, and well tolerated. Although the trial 
reported the efficacy of the combination therapy in preventing PEP, the trial was a 
single-center study with small sample size. Therefore, we conducted a multicenter, 
prospective, randomized controlled trial to evaluate the efficacy of a combination of rectal 
NSAIDs and sublingual nitrate in preventing PEP. 
 
Methods 
Study design 
The study was a 2-arm, multicenter, prospective, randomized, superiority unblinded 
trial to evaluate the combined effect of nitrate and diclofenac in the prevention of PEP, 
in comparison with the efficacy of diclofenac alone. The study was conducted between 
March 2015 and May 2018 at 12 centers in Japan; more than 200 ERCPs per year were 
performed in each center. A total of 900 eligible patients were randomly assigned to 
receive a 50 mg diclofenac suppository either alone or in combination with a 5 mg 
isosorbide dinitrate sublingual tablet. The sublingual isosorbide dinitrate tablets which 
showed maximum blood concentrations at 18.2 min, and the biphasic elimination with 
an initial half-life of 7.5 minutes and a longer terminal half-life of 55.2 minutes [17] were 
administered 5 minutes before the endoscopic procedure, and the diclofenac 
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suppositories were administered within 15 minutes after the endoscopic procedure. 
 
Ethical consideration 
The study protocol was approved by the institutional review board of each of the 
participating institutions before initiating the study. This trial was registered with the 
University Hospital Medical Information Network (Clinical Trial Registry no. 
UMIN000016274). 
 
Endpoints 
Primary and secondary endpoints  
The primary endpoint was the occurrence of PEP. PEP was defined by the criteria set by 
Cotton et al. [18], as the development of abdominal pain and elevation of serum amylase 
levels by more than 3 times the upper normal limit (hyperamylasemia) within 24 h after 
an ERCP. Serum amylase level was measured before the ERCP, and at any time when 
the patient complained of abdominal pain within 24 h after the ERCP; otherwise, it was 
routinely measured 24 h after the ERCP. Secondary endpoints included the development 
of moderate or severe PEP, the frequency of PEP in the patients with the risk factors for 
PEP, AE related to the study drugs. The severity of PEP was graded according to the 
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extension of the planned fasting period after the ERCP as follows, mild: PEP requiring 
an extension of the planned fasting period of less than 3 days; moderate: requiring an 
extension of the planned fasting period of 4–10 days; and severe: requiring an extension 
of the planned fasting period of more than 10 days, necessitating a surgical or intensive 
treatment, or resulting in death. This definition of PEP severity was modified based 
on the criteria of Cotton et al (18). The following factors were considered to be high-
risk for the occurrence of PEP: (1) pre-cut sphincterotomy (a procedure performed to 
facilitate the biliary access when standard cannulation techniques are unsuccessful); (2) 
endoscopic pancreatic sphincterotomy (EPST); (3) endoscopic papillary balloon dilation 
(EPBD) of the intact biliary sphincter; (4) difficult cannulation (more than 10 minutes 
elapsed for the successful selective cannulation, or in failed cannulation, (5) injection of 
contrast agent into the pancreatic duct; (6) female patient, and age < 60 years, (7) clinical 
suspicion of sphincter of Oddi dysfunction (SOD); (8) history of recurrent pancreatitis; 
and (9) history of PEP [11,19]. The patients- and procedure-related factors were recorded 
at the end of procedures. Patient-related factors included the following: (1) age, (2) sex, 
(3) presence of juxtapapillary diverticulum and (4) indication for ERCP. Procedure-
related factors include the following: (1) pancreatography; (2) EPST; (3) pre-cut 
sphincterotomy; (4) endoscopic biliary sphincterotomy; (5) EPBD of the intact biliary 
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sphincter; (6) endoscopic biliary drainage(EBD) without endoscopic sphincterotomy ; (7) 
pancreatic duct stenting; (8) common bile duct-intraductal ultrasonography; (9) 
pancreatic duct-intraductal ultrasonography; (10) common bile duct tissue sampling ; 
cytology and brush; (11) pancreatic duct tissue sampling - cytology and brush; (12) time 
for selective cannulation to the targeted duct which was initiated when cannulation was 
attempted ; (13) total time for the ERCP procedure; and (14) concomitant endoscopic 
ultrasound sonography (EUS) / fine needle aspiration (FNA). 
 
Eligibility Criteria 
The inclusion criteria were applied to patients who were scheduled to undergo an 
ERCP. The exclusion criteria are as follows: (1) evaluated 4 or 5 levels according to the 
Eastern Cooperative Oncology Group Performance Status (ECOG PS)[20];(2) age 
younger than 20 years; (3) body weight less than 50 kg; (4) those cases that were 
expected to have duodenal papilla which were inaccessible by endoscopy; (5) not 
native papilla; (6) presence of acute pancreatitis; (7) presence of chronic pancreatitis; (8) 
presence of pancreatic head cancer with occlusion of the main pancreatic duct; (9) 
contraindication to NSAIDs or nitrate; (10) case of post gastrectomy; (11) serum 
creatinine level, >1.4 mg per deciliter; (12) presence of active peptic ulcer disease; (13) 
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presence of closed angle glaucoma; (14) presence of aspirin-induced asthma; (15) 
currently on nitrate medication; (16) inability to provide written informed consent; (17) 
the subjects deemed inappropriate for the trial. 
 
Randomization 
After confirming the fulfillment of the eligibility criteria, investigators conducted a 
registration to the Data Center by a web-based system. The patients were then 
randomly assigned to receive a 50 mg diclofenac suppository, either alone (diclofenac 
alone group) or in combination with a 5 mg isosorbide dinitrate sublingual tablet 
(combination group) in a 1:1 ratio by a minimization method to maintain a balance 
among the institutions and the patients’ characteristics, namely, age, sex, and primary 
disease (biliary disease vs. pancreatic disease). Investigators and patients were not 
blinded to treatment allocation. 
 
Treatment methods 
Intervention 
Before the endoscopy, the history of each patient was recorded, and a physical 
examination was performed. ERCP was performed with the patients in a prone or 
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semi-prone position, under conscious sedation, and with CO2 insufflation. Pharyngeal 
anesthesia was induced by a topical anesthetic using a lidocaine spray; whereas, 
conscious sedation was induced by an intravenous medication, mainly pethidine 
hydrochloride, and diazepam or midazolam, just before the procedures. We 
administered 20 mL of ulinastatin (150,000 U) solution, a protease inhibitor, by 
intravenous infusion immediately after the ERCP, which is routinely used in our 
institution with the expectation that it will prevent PEP. The ERCP devices used 
were not limited to any specific types. We used a conventional cannulation technique 
involving contrast injection in the first attempt without the use of a guidewire. A 
standard monomer-ionic, iodinated, radiological contrast agent with 60% iodine was 
used as a contrast medium. Injection of the contrast medium allowed visualization of 
the bile duct or pancreatic duct to confirm whether selective cannulation was achieved. 
The cases in which it was difficult to cannulate, we performed a pancreatic guidewire 
placement or pre-cut sphincterotomy to achieve selective cannulation. Pancreatic duct 
stenting was performed to prevent pancreatitis at the endoscopist’s discretion. After 
the procedures, the endoscopists recorded the results, and the patients fasted until the 
blood tests performed the following day confirmed the absence of pancreatitis or other 
AEs. For the purpose of observation, all of the patients in this study were hospitalized 
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for at least 48 hours after the procedure. We assessed the patients the morning after 
the procedure and at any time the patients complained of pain. Abdominal pain was 
defined as new or worsening persistent pain in the epigastric region. Decisions 
regarding the evaluation of AEs following the procedure were left to the discretion of 
the endoscopist. All the authors had access to the study data, and they reviewed and 
approved the final manuscript. 
 
Adverse events 
AEs of the study drugs were monitored during their hospital stay. The AE of diclofenac, 
including gastrointestinal bleeding and renal failure; and that of nitrates, including 
headache, dizziness, and hypotension (systolic blood pressure <90 mmHg or decreased 
by 20%) were monitored. Other post-ERCP AEs, including biliary infection, bleeding, 
and perforation were also monitored in addition to PEP. AE were defined in accordance 
with the American Society for Gastrointestinal Endoscopy lexicon for endoscopic AEs 
[21].  
 
Statistical consideration 
Sample size 
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Previous data from a meta-analysis conducted by Puig et al. [22] indicated that a 
prophylactic administration of rectal NSAIDs reduces the incidence of PEP from 14.5% 
to 7.4%, and the relative risk reduction is 50.7%. Sotoudehmanesh et al. [16] also 
reported that combining rectal NSAIDs with sublingual nitrate reduces the incidence of 
PEP from 15.3% to 6.7%, as compared to that with the administration of NSAIDs alone, 
and the relative risk reduction is 56.2%. We assumed that the incidence of PEP in the 
patients who did not receive any prophylactic medicine for PEP would be 14.6% 
(estimated from previous 5 years’ data obtained from our institutions). We estimated 
that 892 patients (446 per study group) would show at least 80% reduction in the overall 
incidence of PEP (56.2% in both the groups), from 7.4% (in the diclofenac alone group) to 
3.2% (in the combination group), while performing the Fisher’s exact test with a 2-sided 
significance level of 0.05. 
 
Statistical analysis 
Statistical analysis was performed on the basis of modified intention-to-treat analysis 
after excluding cases who were randomized mistake. The Wilcoxon rank sum test was 
performed to compare the continuous data, and the Fisher’s exact test was performed to 
evaluate the non-continuous variables. No interim analysis was done. A P<0.05 was 
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considered statistically significant. All the statistical analyses were performed using a 
JMP Pro 12 (SAS Institute Inc., Cary, NC, USA). The ranges of the continuous values 
were shown as interquartile ranges. 
 
Results 
Patients 
Between March 2015 and May 2018, 10188 patients were scheduled to undergo 
ERCP and assessed for eligibility across 12 centers. After screening, 9288 patients 
met the exclusion criteria and 44 declined to participate. Patients were deemed to 
be inappropriate for trial when their health was unstable due severe cholangitis (n 
= 55), advanced cancer (n = 26), severe comorbidity (n = 15), decompensated 
cirrhosis (n = 11), or advanced age (> 85 years) (n = 36). The remaining 900 patients 
were enrolled for the study (Figure 1). Further, 14 patients (1.6%) were excluded 
because, they had been randomized by mistake; some either fulfilled one of the 
exclusion criteria (n=7) (2 presented with contraindication for the NSAIDs, 2 had a 
history of endoscopic biliary sphincterotomy , 1 had the body weight less than 50 kg, 1 
presented with contraindication for nitrate, 1 manifested the presence of chronic 
pancreatitis ), some declined to give their consent just before the ERCP (n=4), and 
17 
 
some were registered twice (n=3). These patients were ineligible for the trial because, 
determining the effect of the treatment would have been impossible in those.  
In the combination group, 2 patients (0.5%) did not undergo ERCP, since hypotension 
and rash or hypoxia occurred immediately after the administration of nitrate, which 
was thought to be an allergic reaction to nitrate. In the diclofenac alone group, ERCP 
was not performed in one patient due to the natural discharge of choledocholithiasis 
before the procedure; and the primary endpoint could not be evaluated in one patient, 
since fatal pulmonary infarction occurred after the ERCP. These four patients were 
included in the analysis. Finally, the total number of patients include in the analysis 
was 886 (444 in the combination group vs. 442 in the diclofenac alone group). The 
baseline characteristics were similar in both the groups (Table 1). 
The procedure-related parameters in both the groups were similar (Table 2). The 
number of patients at high risk of PEP, defined as having one or more risk factors 
for PEP, were 289 (65.1%) and 300 (67.9%) in the combination and diclofenac alone 
groups, respectively (P = 0.39). Among them, the number of patients with one risk 
for post-ERCP pancreatitis were 163 (36.7%) and 167 (37.8%) (P = 0.78), two risks 
for post-ERCP pancreatitis were 93 (21.0%) and 103 (23.3%) (P = 0.42), and three 
or more risks for post-ERCP pancreatitis were 33 (7.4%) and 30 (6.8%) (P = 0.79) in 
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the combination and diclofenac alone groups, respectively. 
Study outcomes 
The primary outcome, namely, PEP occurred in 67 of the 886 patients (7.6%). Of these, 
25 of the 444 patients (5.6%) developed PEP in the combination group, and 42 of the 
442 patients (9.5%) developed PEP in the diclofenac alone group (relative risk, 0.59; 
95% confidence interval (CI), 0.37-0.95; P=0.03); and this corresponded to an absolute 
risk reduction of 3.9% (number needed to treat [NNT], for preventing one episode of 
PEP, was 26), and a relative risk reduction of 40.8% (Table 3).In this study, all the 
patients were hospitalized for the ERCP procedures; and 67 patients with PEP 
completed the follow-up, necessary to determine the severity of PEP. Moderate or 
severe PEP occurred in 14 of the 886 patients (1.6%): 4 (0.9%) in the combination group 
and 10 (2.3%) in the diclofenac alone group (relative risk, 0.12; 95%CI, 0.13-1.26; 
P=0.12) (Table 3). In this trial, no one developed severe PEP. Among the high-risk 
patients, PEP occurred in 24 of the 288 patients (8.3%) in the combination group, and 
in 39 of the 301 (13.0%) in the diclofenac alone group (relative risk, 0.64; 95%CI, 0.39-
1.03; P=0.08). There was no statistical significance between two groups; however, this 
may be due to the small sample size. The relative risk of patients with no risk factors 
for PEP, patients with one risk factor for PEP, patients with two risk factors for PEP, 
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and patients with more than 2 risk factors for PEP, were 0.31, 0.45, 0.76 and 0.78, 
respectively. Furthermore, the relative benefit of additional sublingual nitrate had a 
tendency to decline according to the number of risk factors for PEP. 
 
Prophylactic pancreatic stent 
In total, 136 patients (15.4%) were given a prophylactic pancreatic stent; all of these 
patients were considered a high risk for PEP. Among them, 10 of the 70 patients 
(14.3%) developed PEP in the combination group, and 7 of the 66 patients (10.6%) 
developed PEP in the diclofenac alone group (P=0.61). 
 
 
Adverse events 
The ERCP-related AEs were the following: (1) The median serum amylase level after 
the procedures was 88 (56–173) IU/L in the combination group and 94(62–198) IU/L in 
the diclofenac alone group (P=0.07); hyperamylasemia was observed in 52 patients 
(11.7%) in the combination group and 65 patients (14.7%) in the diclofenac group 
(P=0.20).  (2) Sphincterotomy site bleeding occurred in 2 patients (0.5%) in the 
combination group, and 0 (0%) in the diclofenac alone group. Both the cases manifested 
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moderate bleeding and recovered with endoscopic hemostasis. Thus, there was no need 
of transfusion; (3) A duodenal perforation occurred in one (0.2%) patient in the 
combination group, and in 2 patients (0.5%) in the diclofenac group after the EST. Of 
the 3 patients, one patient in the diclofenac group underwent surgery 2 days after the 
ERCP, and the remaining 2 patients recovered spontaneously with the conservative 
treatment; (4) Biliary infection occurred in 3 patients (0.7%) in the combination group, 
and in 2 patients (0.5%) in the diclofenac alone group. (Table 3). There was no 
significant difference among the outcomes in both the groups.  
 
The AEs other than the ERCP-related were the following: 35 patients (7.9%) in the 
combination group and 13 (2.9%) in the diclofenac alone group presented mild 
transient hypotension during the ERCP procedures, which improved within several 
minutes, and the incidence rate was significantly higher in the combination group 
(P=0.002). In all cases, the hypotension was treated and responded to an intravenous 
bolus infusion of lactated ringer’s solution and/or administration of a temporary 
vasopressor (Table 3). Among the patients who developed PEP in the combination 
group, only one patient presented with transient hypotension during the procedures.  
In the combination group, only one patient (0.2%) complained of headache. 
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Hypotension and rash or hypoxia, which were thought to be an allergic reaction to 
nitrate, occurred in 2 patients in the combination group; however, improved promptly 
by the administration of temporary vasopressors, steroids, and antihistamines. There 
was no serious adverse effect related to the additional administration of nitrate. 
One patient in the diclofenac alone group developed fatal pulmonary infarction a few 
hours after the ERCP. The patient had an advanced cholangiocarcinoma, and had been 
diagnosed with pulmonary arterial thrombosis before the ERCP.   
 
Discussion 
Rectal administration of the NSAIDs has been widely used for the prevention of PEP, 
and has been recommended to be administered in all patients without 
contraindications in the ESGE and JHBPS guidelines [11, 12 ]. 
In this multicenter, randomized controlled trial, we found that the combination 
therapy with diclofenac and sublingual nitrate significantly reduced the incidence of 
PEP as compared to that with the use of diclofenac alone; and it reduced the risk of 
PEP by 40.8%. The number of ERCP patients who were needed to be treated for 
preventing an episode of pancreatitis was 26.  
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Medication with nitrate, especially the sublingual administration, for prophylactic use 
before the ERCP reduced the incidence of PEP in meta-analysis [23,24,25 ]. Glyceryl 
trinitrate (GTN) can reduce the pressure of sphincter of Oddi [15]. Theoretically, the 
use of these compounds before and after an ERCP can relax the biliary and pancreatic 
sphincters, and minimize potential pancreatic outflow obstruction after the procedure. 
Moreover, nitrates produce nitric oxide that causes dilation of the microvascular 
vessels, which may improve pancreatic tissue circulation and nutrition [26]. These 
effects of nitrate may reduce the incidence of PEP. Recently, the study reported by 
Sotoudehmanesh showed that combination of rectal NSAIDs and sublingual isosorbide 
dinitrate, significantly reduces the incidence of PEP than that by the NSAIDs 
suppository alone (from 15.3% to 6.7%). In this study, the time and dose of 
administration of rectal NSAIDs varied from the previous studies; however, our result 
was consistent with that of the previous studies [16]. 
 
We observed a higher rate of PEP in the diclofenac alone group than that reported in 
previous studies [7-9]. This might have resulted from the use of low dose diclofenac or 
the use of a different cannulation method. In some randomized controlled trials [27-30], 
rectal NSAIDs showed significantly better prophylactic activity in PEP. The 
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recommended dose, and that used in these trials, of rectal NSAIDs is 100 mg of 
diclofenac or indomethacin, which is higher than the dose used in the current trial. 
However, 100 mg of diclofenac is not legally permitted in Japan. Previous studies 
reported the efficacy of 50 mg of diclofenac in the prevention of PEP, but the difference 
between the efficacies of 100 mg and 50 mg of diclofenac was not clear [31]. 
In addition, we used a conventional cannulation technique involving contrast injection 
in the first attempt. For this study, this was thought to be inferior in terms of the 
incidence of PEP [32-36]. There is no significance difference in the PEP rates in high-
risk patients between the two groups (p=0.08).However, the combination group 
patients tended to show a low incidence of pancreatitis; it is possible that the lack of 
significance may be due to the small sample size.  
 
Several prophylactic interventions have been proved to be effective in minimizing the 
risk of PEP, including pancreatic stent placement [11, 37]. In the present study, 
pancreatic stents were used in 15.4% of all the patients. The pancreatic stent was 
used at the discretion of the endoscopists and the pancreatic stent placement was 
attempted in patients who were considered at high risk of developing PEP. 
Therefore, we could not accurately evaluate the usefulness of a prophylactic 
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pancreatic stent for preventing PEP in this study. 
 
The only significant AE attributable to the combination group was hypotension. In the 
combination group, 7.9% of the patients manifested hypotension for a transient period 
as compared to 2.9% of the patients the diclofenac alone group who also manifested 
hypotension, which responded to conventional therapy. In addition, the allergic 
reaction related to nitrate occurred in 2 patients, which improved promptly; and no 
serious AEs concerning the use of nitrate were detected in our study. Prophylaxis 
should be cost-effective, safe, and affordable. A combination of rectally administered 
diclofenac and sublingual nitrate has been thought to be an ideal pharmacologic 
prophylaxis: it is inexpensive, safe, and easy to apply to fasting patients. 
 
Our study has some limitations; one such limitation is the lack of a double-blind 
clinical setting which introduces the possibility of a bias in the evaluation of PEP and 
the lack of data regarding the baseline abdominal pain may be a probable 
confounder in terms of defining PEP. A further limitation is that the patients received 
a 50 mg rectal dose of diclofenac after the ERCP which is lower than that reported in 
the previous studies. The third limitation is that all patients were administered 
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ulinastatin, with the expectation that this would prevent PEP; we recognize that this 
may affect the incidence of PEP and introduce an additional variable into this study. 
The fourth limitation is that we overestimated the risk reduction rate of the additional 
administration of sublingual nitrate, and a larger number of cases were needed to 
obtain a planned statistical power. The result of this study has a possibility of a type Ⅰ
statistical error reflected by a confidence interval nearly 1.0. Therefore, additional 
confirmatory studies will be necessary to support our conclusions. 
 
In conclusion, a combination of rectally administered diclofenac and sublingual nitrate 
significantly reduces the incidence of post-ERCP pancreatitis when compared with 
diclofenac alone. 
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Table1  Patients characteristics 
 
 
Combination  
group 
Diclofenac 
alone group 
 n=444 n=442 
Age, year, median (range) 68(59-76) 68(59-76) 
Sex, male, n (%) 286 (64.4) 286 (64.7) 
Indication, n (%) 
  
 Biliary disease 372 (83.8) 376 (85.1) 
     Choledocholithiasis 229 (51.6) 238 (53.9) 
     Suspected for SOD 3 (0.7) 0 (0) 
     Other benign biliary disease 49 (11.0) 52 (11.8) 
     Malignant biliary disease 91 (20.5) 86 (19.5) 
 Pancreatic disease 72 (16.2) 66 (14.9) 
     PDAC 31 (7.0) 20 (4.5) 
     IPMN 18 (4.1) 25 (5.7) 
     Other pancreatic disease 23 (5.2) 21 (4.8) 
History of recurrent pancreatitis, n (%) 6 (1.4) 5 (1.1) 
Previous history of post-ERCP pancreatitis, n (%) 1 (0.2) 1 (0.2) 
 
SOD, sphincter of Oddi dysfunction; PDAC, pancreatic ductal adenocarcinoma, 
IPMN, intraductal papillary mucinous neoplasm; ERCP, endoscopic retrograde 
cholangiopancreatography 
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Table2 Procedure-related parameters 
  Combination group Diclofenac alone group P-value 
  n=444 n=442   
Parameters related to cannulation    
Main target duct, n (%)   0.85  
     Common bile duct  374 (84.2) 375 (84.8)  
     Pancreatic duct 70 (15.8) 67 (15.2)  
Success rate of selective cannulation, n (%) 438 (98.7) 431 (97.5) 0.23 
     Common bile duct  368/374 (98.4) 364/375 (97.1) 0.33 
     Pancreatic duct 70/70 (100) 67/67 (100) 0 
Precut sphincterotomy, n (%) 20 (4.5) 15 (3.4) 0.49 
Endoscopic pancreatic sphincterotomy, n (%) 14 (3.2) 12 (2.7) 0.84 
Time for selective cannulation, min (range) 5 (2-11) 5 (2-11) 0.84 
Difficult cannulation, n (%) * 142 (32.0) 139 (31.4) 0.89 
Presence of juxtapapilla diverticulum, n (%) 122 (27.6) 99 (22.5) 0.09 
Parameters related to biliary procedures    
Endoscopic biliary sphincterotomy, n (%) 277 (62.4) 278 (62.9) 0.89 
Common bile duct-intraductal ultrasonography, n (%) 103 (23.2) 93 (21.0) 0.44 
Common bile duct-tissue sampling, n (%) 52 (11.7) 59 (13.4) 0.48 
Endoscopic biliary drainage without endoscopic sphincterotomy, n (%) † 48 (10.8) 41 (9.3) 0.50  
Endoscopic papillary balloon dilation of intact biliary sphincter, n (%) 21 (4.7) 18 (4.1) 0.74 
Parameters related to pancreatic duct procedures    
Pancreatic injection, n (%) 215 (48.4) 228 (51.6) 0.38 
Placement of pancreatic duct stent, n (%) 70 (15.8) 66 (14.9) 0.78 
Pancreatic duct-intraductal ultrasonography, n (%) 10 (2.3) 15 (3.4) 0.32  
Pancreatic duct-tissue sampling, n (%) 7 (1.6) 4 (1.0) 0.55 
Others    
ERCP procedure time, min (range) 28 (18-47) 30 (19-46) 0.40  
Concomitant EUS/FNA, n (%) 72 (16.2) 87 (19.7) 0.19 
 
*: Difficult cannulation is defined as cases where more than 10 minutes elapse 
before successful selective cannulation, or those with failed cannulation to the 
target duct. 
†: Endoscopic biliary drainage without endoscopic sphincterotomy is defined as the 
deployment of plastic or metallic stents to the bile duct without biliary 
sphincterotomy. 
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ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic 
ultrasound;  FNA, fine needle aspiration 
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Table3 The incidence of post-ERCP pancreatitis and other adverse events 
 
  
Combination  
group 
Diclofenac alone 
group P-value Relative risk 95%CI 
  n=444 n=442 
Post-ERCP pancreatitis in all patients, n (%) 25 (5.6 ) 42 (9.5) 0.03 0.59  0.37-0.95 
   Mild 21 (4.7) 32 (7.2) 0.12 0.65  0.38-1.11 
   Moderate 4 (0.9) 10 (2.3) 0.12 0.40  0.13-1.26 
   Severe 0 (0) 0 (0)    
Post-ERCP pancreatitis in patients with no risk factor 1/155 (0.7) 3/142 (2.1) 0.27 0.31  0.03-2.90 
Post-ERCP pancreatitis in patients with risk factor 24/288 (8.3) 39/301 (13.0) 0.08 0.64  0.39-1.03 
Post-ERCP pancreatitis in patients with 1 risk factor 7/163(4.3%) 16/167(9.6%) 0.08 0.45 0.19-1.06 
Post-ERCP pancreatitis in patients with 2 risk factors 11/93(11.8%) 16/103(15.5%) 0.54 0.76 0.37-1.56 
Post-ERCP pancreatitis in patients with more than 2 risk factors 6/33 (18.2) 7/30 (23.3) 0.76 0.78  0.29-2.06 
Adverse events related to ERCP      
Bleeding, n (%) 2 (0.5) 0 (0) 0.50  N/A  
      Mild 0 0    
      Moderate 2 0    
Perforation, n (%) 1 (0.2) 2 (0.5) 0.62 0.50  0.05-5.47 
      Moderate 1 1    
      Severe 0 1    
Biliary infection, n (%) 3 (0.7) 2 (0.5) 1.0  1.49  0.25-8.89 
      Mild 1 1    
      Moderate 2 1       
Adverse events other than the ERCP-related      
Hypotension, n (%) 35 (7.9) 13 (2.9) 0.002 2.69 1.44-5.01 
Headache, n (%) 1 (0.2) 0 (0) 1.0  N/A  
Drug allargic reaction, n (%) 2 (0.5) 0 (0) 0.50 N/A  
Pulmonary infarction, n (%) 0 (0) 1 (0.2) 0.50    
 
ERCP, endoscopic retrograde cholangiopancreatography; CI, confidence interval; N/A, 
not available 
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Figure legends 
Figure 1: Patient flow diagram showing the combined use of rectal diclofenac with 
sublingual isosorbide dinitrate vs. diclofenac alone for the prevention of post-ERCP 
pancreatitis. 
 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; NSAIDs, non-
steroidal anti-inflammatory drugs; ERCP, endoscopic retrograde 
cholangiopancreatography. AE, adverse event 
